MBX Biosciences is trading 4.2% down at $58.15 as broader pressure on biotech and growth stocks weighs on the share price.
- The move comes despite a lack of fresh company-specific news, FDA updates, or earnings catalysts today.
- Shares have seen recent volatility following positive Phase 3 planning updates and changes to the leadership team.
- Today's decline appears largely driven by risk-off sentiment affecting both the biotech sector and broader market indices.